Drugs / SPH5030
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05245058 | Jan 2022 → Dec 2026 expected | carcinoma | Shanghai Pharmaceuticals Holding Co., Ltd | Recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT06372223 | Mar 2024 | neoplasm | Shanghai Pharmaceuticals Holding Co., Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06434597 | Jul 2024 → Dec 2026 expected | digestive system cancer | Shanghai Pharmaceuticals Holding Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPH5030 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06372223 ↗ |
| Modality | Small molecule | — CHEMBL6068562 ↗ |
| Route | Oral | “orally” NCT05245058 ↗ |